trial

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

NCTId NCT04187560
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 64 (actual)
Sponsored by LB Pharmaceuticals Inc.
Primary completion 2020-07-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
64 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
Double
Start
2020-01-22
Primary completion
2020-07-01
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
LB-102

Sponsors

LB Pharmaceuticals Inc.Lead Sponsor

Investigators

1
Lukasz Biernat, PhDPrincipal Investigator

Sites

1 total
Cincinnati, United States

Facts & assertions

4 sourced
Enrollment
64
Phase
PHASE1
Primary Completion Date
2020-07-01
Status
COMPLETED
relationships
The graph out of here
drug
LB-102
drug
lead_sponsor
LB Pharmaceuticals Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Lukasz Biernat, PhD
person